Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

AS 900672-Enriched

X
Drug Profile

AS 900672-Enriched

Alternative Names: AS900672-Enriched; Follicle-stimulating hormone analogue - Merck Serono; FSH analogue - Merck Serono; Glycosylated recombinant follicle-stimulating hormone; Glycosylated recombinant FSH; Hyperglycosylated FSH - Merck Serono; Long-acting follicle stimulating hormone - Merck Serono; Long-acting FSH - Merck Serono

Latest Information Update: 07 Aug 2015

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Merck Serono
  • Developer EMD Serono
  • Class Follicle stimulating hormones; Infertility therapies; Pituitary gonadotropins
  • Mechanism of Action Ovarian follicle stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Female infertility

Most Recent Events

  • 30 Sep 2008 Merck KGaA completes a phase II trial for Female infertility in USA (NCT00505752)
  • 03 Jul 2007 Phase I development is ongoing for Female infertility
  • 08 Jan 2007 Serono is now called Merck Serono
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top